Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended September 29, 2007 (Fiscal Year 2008)
Business Overview: Haemonetics designs, manufactures, and markets automated blood management systems, including devices for blood collection, processing, and surgical salvage, along with related disposables and software solutions. The company operates globally with significant revenue generated outside the U.S.
Key Financial Metrics
| Metric (in thousands) | Q2 FY08 (3 Months) | Q2 FY07 (3 Months) | YTD FY08 (6 Months) | YTD FY07 (6 Months) |
|---|---|---|---|---|
| Net Revenues | $121,179 | $108,487 | $243,115 | $219,161 |
| Gross Profit | $59,889 | $55,162 | $121,383 | $112,535 |
| Gross Margin | 49.4% | 50.8% | 49.9% | 51.3% |
| Operating Income | $14,616 | $5,156 | $30,395 | $20,047 |
| Operating Margin | 12.1% | 4.8% | 12.5% | 9.1% |
| Net Income | $11,167 | $1,266 | $23,844 | $12,422 |
| Diluted EPS | $0.42 | $0.05 | $0.89 | $0.44 |
| Cash & Equivalents | $154,983 (as of Sept 29, 2007) | |||
| Working Capital | $271,066 (as of Sept 29, 2007) | |||
| Net Debt Position | $130,705 (Net Cash) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 11.7% in Q2 and 10.9% YTD compared to the prior year. Growth was driven by increases in disposables (plasma, blood bank, OrthoPAT), software solutions, and equipment sales. Foreign exchange rates had a slight negative impact (-0.9% in Q2).
- Profitability Surge: Operating income increased 183.5% in Q2 and 51.6% YTD. This significant improvement is largely attributable to the absence of a $9.1 million in-process research and development (IPR&D) charge recorded in Q2 FY07 related to the Arryx, Inc. acquisition.
- Net Income: Net income increased 782.1% in Q2 and 91.9% YTD. The increase was driven by higher operating income and a lower effective tax rate (32.8% in Q2 FY08 vs. 82.2% in Q2 FY07).
- Operating Expenses: Total operating expenses decreased 9.5% in Q2 and 1.6% YTD, primarily due to the non-recurrence of the IPR&D charge. However, Selling, General, and Administrative (SG&A) expenses increased due to ERP implementation costs and sales support.
Guidance, Outlook, and Risks
- Acquisition Activity: On October 30, 2007 (subsequent to period end), the company announced a definitive agreement to acquire Haemoscope's TEG Thrombelastograph Hemostasis Analyzer business for $44 million in cash.
- Restructuring: The company is consolidating customer support functions in Europe into its headquarters in Signy, Switzerland. Expected exit costs are $4 million to $5 million, with anticipated annual operating savings of approximately $1.5 million.
- Capital Allocation: The company completed a $75 million share repurchase program in the first six months of FY08, purchasing approximately 1.46 million shares.
- ERP Implementation: The company is implementing a global Oracle ERP system. Significant go-live milestones were achieved in Europe, Japan, and Asia during the quarter, with U.S. implementation occurring in the subsequent quarter. This has increased operating expenses temporarily.
- Foreign Exchange Risk: Approximately 55.6% of sales are generated outside the U.S. The company uses forward contracts to hedge anticipated cash flows, but a strengthening U.S. dollar remains a risk to reported results.
- Tax Outlook: Management expects an annual tax rate of approximately 34.4% for the remainder of fiscal year 2008.
Key Facts for Investor Verification
- One-Time Charges: Verify the impact of the $9.1 million IPR&D charge in the prior year Q2, which significantly distorts year-over-year operating income comparisons.
- Foreign Exchange Impact: Assess the sensitivity of future earnings to fluctuations in the Euro and Japanese Yen, as over 55% of revenue is international.
- Acquisition Integration: Monitor the integration and financial contribution of the newly acquired Haemoscope TEG business and the IDM software acquisition.
- ERP Costs: Track the timeline and cost overruns associated with the global ERP implementation, which is currently driving SG&A expenses.
- Share Repurchases: Confirm the status of the completed $75 million buyback program and any future capital return plans.